Trial Summary
What is the purpose of this trial?This is an open-label pilot study of tamoxifen as chemoprevention in patients with pancreatic mucinous cystic neoplasms (MCN) who will not undergo immediate resection. Up to 15 participants will be enrolled and take tamoxifen 20mg by mouth daily for up to 24 weeks.
Eligibility Criteria
This trial is for individuals with certain types of non-cancerous pancreatic cysts known as mucinous cystic neoplasms (MCNs) who are not scheduled for immediate surgery to remove these cysts. Specific eligibility details are not provided.Treatment Details
The study is testing the effectiveness of a medication called Tamoxifen, taken orally at a dose of 20mg daily, in preventing cancer in patients with MCN. Up to 15 participants will be involved and the treatment duration is up to 24 weeks.
1Treatment groups
Experimental Treatment
Group I: TamoxifenExperimental Treatment1 Intervention
Tamoxifen 20mg by mouth daily for up to 6 months
Tamoxifen is already approved in European Union, United States, Canada, Japan, Australia for the following indications:
🇪🇺 Approved in European Union as Nolvadex for:
- Breast cancer
- Infertility
- Gynecomastia
🇺🇸 Approved in United States as Tamoxifen citrate for:
- Breast cancer
- Reduction in breast cancer incidence in high-risk women
- McCune-Albright Syndrome
🇨🇦 Approved in Canada as Tamoxifen for:
- Breast cancer
- Reduction in breast cancer incidence in high-risk women
🇯🇵 Approved in Japan as Tamoxifen for:
- Breast cancer
🇦🇺 Approved in Australia as Tamoxifen for:
- Breast cancer
- Infertility
- Gynecomastia
Find a clinic near you
Research locations nearbySelect from list below to view details:
University of Nebraska Medical CenterOmaha, NE
Loading ...
Who is running the clinical trial?
University of NebraskaLead Sponsor